checkAd

     105  0 Kommentare Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone - Seite 3

    Further, a toric IOL corrects astigmatism only when it is placed in the correct position in the eye. There is a possibility that the toric IOL could be placed incorrectly or could move within the eye. If the toric lens is not positioned correctly following surgery, the change in your astigmatism correction by the IOL, along with any necessary correction with glasses, may cause visual distortions. If the lens rotates in your eye, you may need additional surgery to reposition or replace the IOL.

    About Alcon

    Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

    References

    1. Market Scope - 2023 Premium Cataract Surgery Market Report; 2023 IOL Market Report.
    2. Alcon Data on File; U.S. Pat. Nos. RE45,969, 9,968,440, 11,083,566.
    3. AcrySof IQ Vivity or Clareon Vivity IOL Directions for Use.
    4. Reus NJ, Kooijman M, Perez-Vives C. Overall Visual Outcomes from a Real-world Study of Presbyopia-correcting IOLs in a Large Population. Presented at the European Society of Cataract and Refractive Surgery (ESCRS) Annual Meeting; 8-12 Sept. 2023; Vienna, Austria.
    5. Alcon Data on File, 2024. REF-22137.
    6. Alcon IOL Global Sales; Jan. 2021-Nov. 2022.

    *Based on independent market audit - Market Scope - 2023 Premium Cataract Surgery Market Report.
    +The Vivity Registry Study was a multicentre, ambispective, non-comparative, open-label, non-interventional registry study conducted across 41 sites from eight (8) countries: Australia, Belgium, Germany, New Zealand, the Netherlands, Portugal, Spain and the United Kingdom.
    Subject satisfaction was evaluated with the Catquest 9SF Questionnaire. Statistic refers to ‘very’ or ‘fairly’ satisfied.
    Visual disturbances were evaluated by asking open, non-prompted questions about visual experience.

    Connect with us on
    Facebook
    LinkedIn

    2024 Alcon Inc. 03/24 GLB-VIV-2400001

    Lesen Sie auch


    The Alcon Stock at the time of publication of the news with a raise of +0,32 % to 78,60EUR on Lang & Schwarz stock exchange (06. März 2024, 14:04 Uhr).
    Seite 3 von 3



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone - Seite 3 Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) have surpassed more than one …